Жанры
Авторы
Контакты
О сайте
Книжные новинки
Популярные книги
Найти
Главная
Авторы
Sheila Annie Peters
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
Читать книгу Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations - Sheila Annie Peters - Страница 1
Оглавление
Предыдущая
Следующая
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
...
60
Оглавление
Купить и скачать книгу
Вернуться на страницу книги Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
Оглавление
Страница 1
Table of Contents
List of Tables
List of Illustrations
Guide
Pages
Страница 7
Страница 8
Страница 9
Страница 10
Страница 11
Страница 12
Страница 13
Страница 14
1 A REVIEW OF PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES CONTENTS
1.1 INTRODUCTION
1.2 PHARMACOKINETIC PRINCIPLES 1.2.1 Routes of Drug Administration
1.2.2 Intravenous Bolus
1.2.2.1 Zero‐ and First‐Order Kinetics
1.2.2.2 Clearance, Volume of Distribution, Half‐life, and AUC
1.2.3 Plasma Protein Binding and Blood–Plasma Ratio
1.2.4 Hepatic, Renal, and Biliary Clearances
1.2.4.1 Hepatic Clearance
1.2.4.2 Hepatic Extraction
1.2.4.3 Renal Clearance
1.2.4.4 Biliary Clearance
1.2.5 Extravascular (Subcutaneous, Intramuscular, and Per Oral) Absorption
1.2.6 Absorption from Solid Dosage Forms
Box 1.1
1.2.7 Role of Transporters in ADME
1.2.8 Linear and Non‐Linear Pharmacokinetics
1.2.9 Intravenous Infusion, Repeated Dosing, Steady State Kinetics, and Accumulation
1.2.10 Active Metabolite and Prodrug Kinetics
1.2.10.1 Active Metabolites
1.2.10.2 Prodrugs
1.2.10.3 Metabolite Kinetics
1.2.10.4 Limiting Conditions
1.2.10.5 Drug‐Metabolite Plasma Concentration Relationships After Single Drug Administration
1.2.10.6 Steady‐State Metabolite Kinetics
1.2.10.7 First‐Pass Metabolite Production
1.3 PHARMACOKINETIC VARIABILITY
1.4 PHARMACOKINETICS OPTIMIZATION IN DRUG DISCOVERY
1.5 PHARMACODYNAMIC PRINCIPLES
1.5.1 Pharmacological Targets and Drug Action
1.5.2 Functional Adaptation Processes
1.5.2.1 Desensitization, Tolerance, and Tachyphylaxis
1.5.3 Biomarkers, Surrogate Endpoints, and Clinical Endpoints
KEYWORDS
REFERENCES
2 A REVIEW OF DRUG–DRUG INTERACTIONS CONTENTS
2.1 INTRODUCTION
2.2 DRUG INTERACTIONS MEDIATED BY ENZYMES AND TRANSPORTERS AT VARIOUS SITES
2.3 FACTORS AFFECTING DDI
2.4 IN VITRO METHODS TO EVALUATE DRUG–DRUG INTERACTIONS
2.4.1 Candidate Drug as a Potential Perpetrator
2.4.2 Candidate Drug as a Potential Victim of Inhibition
2.5 SOURCES OF UNCERTAINTY
2.6 THERAPEUTIC PROTEIN–DRUG INTERACTION
KEYWORDS
REFERENCES
{buyButton}
Подняться наверх
